Long-term duration of protection of ancestral-strain monovalent vaccines and effectiveness of the bivalent BA.1 boosters against COVID-19 hospitalisation during a period of BA.5, BQ.1, CH.1.1. and XBB.1.5 circulation in England

Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2023.03.31.23288018

Article usage

Article usage: March 2023 to August 2025

AbstractFullPdf
Mar 2023239029
Apr 20233316143736
May 20233042286
Jun 20233341270
Jul 20231462047
Aug 2023891334
Sep 202371418
Oct 202345415
Nov 202356413
Dec 20232605
Jan 20242127
Feb 20241421
Mar 20241829
Apr 20241557
May 20241824
Jun 20241328
Jul 20241729
Aug 20242136
Sep 20242229
Oct 2024726
Nov 202425417
Dec 20241023
Jan 20252115
Feb 202521176
Mar 2025392518
Apr 202531111
May 202532715
Jun 2025452613
Jul 2025221610
Aug 2025201
Back to top
Posted March 31, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Long-term duration of protection of ancestral-strain monovalent vaccines and effectiveness of the bivalent BA.1 boosters against COVID-19 hospitalisation during a period of BA.5, BQ.1, CH.1.1. and XBB.1.5 circulation in England
Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2023.03.31.23288018; doi: https://doi.org/10.1101/2023.03.31.23288018
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area